Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2145)	10/5/2009 1:30:15 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

DEPO is still up 26.30% on volume of 3,880,300 > 10x its ADV The stock opened with a good UG and traded earlier as H as $6.21 above its July 2006 H of $6.06 <g> bigcharts.marketwatch.com It announced top-line results from a PIII demonstrating that DM-1796 achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo. DM-1796 is an investigational extended release, once-daily tablet formulation of gabapentin for the treatment of PHN. DEPO it to Solvay Pharmaceuticals in the US, Canada and Mexico for the treatment of pain. An NDA for DM-1796 for the treatment of PHN is expected to be submitted to the FDA by the end of 1stQ in 2010. DEPO has 3Qs of better revenues and higher losses.The loss for this YR. is still expected higher than in 2008. The ACTAY is $5.50 but it seems that with further good news it could test the resistance at $7 However, it seems better to wait for it to close today's UG.<g> bigcharts.marketwatch.com Bernard